Simultaneous measurement of both active and total TGF-β levels in various pathological specimens would help us understand the mechanism of progressive disorders including fibrotic diseases, chronic inflammatory disorders, heart failure, and cancers in clinical settings. This evidence concerns the gene TGFB1 and cancer.